Natreon Inc. Published in The Journal of Clinical and Diagnostic Research
FOR IMMEDIATE RELEASE
New Brunswick, NJ, June 2015 – Natreon’s AyuFlex®, a clinically studied and standardized aqueous extract of Terminalia chebula, significantly increases pain threshold and pain tolerance time according to a human clinical study just published in The Journal of Clinical and Diagnostic Research. AyuFlex® is a GRAS-approved and patented ingredient for joint health and pain relief. Pain is defined as an unpleasant sensory and emotional experience associated with or without tissue damage. Analgesics decrease the sensation of pain by increasing the threshold of pain to external stimuli with no change in the level of consciousness. Traditionally, NSAIDs have been the mainstay of treatment for acute and chronic pain conditions. However, the risks of gastrointestinal toxicity and renal impairment have led to the search for alternative analgesics with fewer adverse effects, such as Terminalia chebula.
In this randomized, double blind, placebo controlled crossover study, 12 healthy human volunteers received either a single oral dose of 1000mg of AyuFlex® or identical placebo capsules. A hot air analgesiometer, which is a thermal pain model for testing the analgesic activity of drugs, was used to deliver thermal pain stimuli to the subjects. Mean pain threshold time and mean pain tolerance time were measured 180 minutes post drug administration. A washout period of two weeks was given for crossover between the two treatments. Results from the study showed that treatment with AyuFlex® significantly increased mean percentage change in pain threshold time and pain tolerance time compared to placebo. The increase in mean percentage change for pain threshold time and pain tolerance time was 20.42% (p < 0.001) and 17.5% (p < 0.001) respectively. There were no adverse effects reported for either treatment group. Due to its positive safety profile and ability to increase pain threshold and tolerance, AyuFlex® may be a good choice for acute or chronic painful ailments, especially in patients who may be at higher risk for gastrointestinal or renal complications.
Natreon, Inc. is continuing its commitment to research and development with additional controlled clinical studies to evaluate the analgesic efficacy and safety of AyuFlex®.
The full study is available at: www.jcdr.net/articles/PDF/5916/11369_CE[Ra]_F(P)_PF1(VSUAK)_PFA(P)_PF2(PAG).pdf
About Natreon, Inc.:
Natreon Inc. is a 16 year old company located in New Jersey with a state of the art R&D facility in Kolkata, India, and is focused on developing and marketing Ayurvedic products backed by extensive research, high degree of standardization, multiple clinical studies, safety studies, and intellectual property. Natreon’s R&D team is headed by Prof. Shibnath Ghosal, a Fulbright scholar and an eminent natural product chemist with hundreds of publications in scientific journals and a group of Ph.D. and Master’s level scientists. Natreon’s scientific research includes process optimization, development of chromatographic analytical methods such as HPLC, HPTLC, GC-MS and LC-MS for standardization, development of marker compounds, and pharmacological studies. Safety studies are done in the USA and clinical studies are conducted in reputed institutes in India as well as the USA. For more information on AyuFlex® and Natreon’s other patented ingredients, please visit www.natreoninc.com.
Natreon, Inc. Key Executives:
Dr. Sanni Raju – CEO/Chairman
Jeff Lind – VP Sales and Marketing
Dr. Aparna Kalidindi – Manager, Technical Sales and Marketing